Citations

Mayo Clinic

Showing 10 of 108602 citations.

Abstract 42: Artificial Intelligence Electrocardiogram to Detect Coronary Calcification and to Predict Atherosclerotic Cardiovascular Events in the Community
Medina‐Inojosa, Betsy J. , Shelly, Michal, Suárez, Abraham Báez, Friedman, Paul D., Lopez‐Jimenez, Francisco, Medina‐Inojosa, José R. , Attia, Zachi I. , Friedman, Paul, Carter, Rickey E. , López-Jiménez, Francisco

Circulation | March 14, 2023 | Volume: 147 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.147.suppl_1.42 Get It

Background: We developed a deep learning algorithm that detects coronary artery calcium (CAC) score using 12-lead electrocardiograms (CAC- ECG). We tested the hypothesis that the output from the CAC-ECG algorithm would be associated with incident atherosclerotic cardiovascular disease (ASCVD) events and that the CAC- ECG would refine the AHA/ACC Pooled Cohort Equation’s (PCE) predictive capabilities. Methods: A community-based cohort of consecutive patients seeking primary care in Olmsted County, MN, between 1998-2000 with passive follow-up via record linkage. Inclusion was identical to the PCE. The original CAC-ECG was developed in 43,210 subjects yielding an AUC of 0.83. Herein, we used the CAC-ECG output to predict a high CAC (≥ 300). Primary outcome was ASCVD defined as fatal and non-fatal myocardial infarction and ischemic stroke, secondary outcome was Major Adverse Cardiovascular Events (MACE) further including PCI, CABG, and mortality. Events were validated in duplicate. Cox proportional hazard models adjusted for variables included in the PCE and were stratified to evaluate the effect of the CAC-ECG on PCE-predicted risk. Follow-up was truncated at 10 years for PCE analyses. Results: We included 24,793 subjects, mean ± SD age 53.9 ± 12.1, 52% women, 95% white. After 16.7±3.7 yrs follow-up, 2,366 (9.5%) had ASCVD and 3,401 (13.7%) had MACE. Risk of ASCVD and MACE increased with CAC-ECG probability quintiles, independent of risk factors, p for trend <0.001 ( Fig. A-B ). The CAC-ECG enhanced the predicted capabilities of the PCE across all ASCVD risk groups ( Fig. C ). Net reclassification improved 13.7% with comparable C-statistic from 0.77 vs. 0.78 for PCE and CAC-ECG. Conclusions: CAC-ECG was associated with ASCVD and MACE and improved PCE predicted risk. The CAC-ECG algorithm could identify individuals at risk in primary prevention; Unlike the PCE, the CAC-ECG can be applied without chart review or performing a computer tomography and may be reliably used retrospectively in cohorts with digitally stored ECGs.
Opportunistic Screening for Atrial Fibrillation on Routine Chest Computed Tomography
Parker, William , Vigneault, Davis M. , Yang, Issac, Bratt, Alex , Marquardt, Alizee C., Sharifi, Husham , Guo, H. Henry , Parker, William A

Journal of Thoracic Imaging | March 14, 2023 | Volume: 38 | Issue: 5 | Pages: 270-277

10.1097/rti.0000000000000702 | PMID 36917506 Get It

Purpose: Quantitative biomarkers from chest computed tomography (CT) can facilitate the incidental detection of important diseases. Atrial fibrillation (AFib) substantially increases the risk for comorbid conditions including stroke. This study investigated the relationship between AFib status and left atrial enlargement (LAE) on CT. Materials and Methods: A total of 500 consecutive patients who had undergone nongated chest CTs were included, and left atrium maximal axial cross-sectional area (LA-MACSA), left atrium anterior-posterior dimension (LA-AP), and vertebral body cross-sectional area (VB-Area) were measured. Height, weight, age, sex, and diagnosis of AFib were obtained from the medical record. Parametric statistical analyses and receiver operating characteristic curves were performed. Machine learning classifiers were run with clinical risk factors and LA measurements to predict patients with AFib. Results: Eighty-five patients with a diagnosis of AFib were identified. Mean LA-MACSA and LA-AP were significantly larger in patients with AFib than in patients without AFib (28.63 vs. 20.53 cm2, P<0.000001; 4.34 vs. 3.5 cm, P<0.000001, respectively), both with area under the curves (AUCs) of 0.73. Multivariable logistic regression analysis including age, sex, and VB-Area with LA-MACSA improved the AUC for predicting AFib (AUC=0.77). An LA-MACSA threshold of 30 cm2 demonstrated high specificity for AFib diagnosis at 92% and sensitivity of 48%, and LA-AP threshold at 4.5 cm demonstrated 90% specificity and 42% sensitivity. A Bayesian machine learning model using age, sex, height, body surface area, and LA-MACSA predicted AFib with an AUC of 0.743. Conclusions: LA-MACSA or LA-AP can be rapidly measured from routine chest CT, and when >30 cm2 and >4.5 cm, respectively, are specific indicators to predict patients at increased risk for AFib.
Postmortem Cerebellar Volume Is Not Reduced in Essential Tremor: A Comparison with Multiple System Atrophy and Controls
Tremblay, Cécilia , Dunckley, Nathaniel, Zhang, Nan , Fiock, Kimberly L. , Driver‐Dunckley, Erika , Mehta, Shyamal H. , Shill, Holly A. , Beach, Thomas G. , Driver-Dunckley, Erika, Serrano, Geidy E. , Adler, Charles H.

Journal of Parkinson’s Disease | March 14, 2023 | Volume: 13 | Issue: 3 | Pages: 333-340

10.3233/jpd-225033 | PMID 36938740 Get It

Background: Essential tremor (ET) is a common movement disorder in which cerebellar microscopic and volume alterations have been repeatedly reported although with disagreement between studies. However, pronounced heterogeneity was found with regard to cerebellar volume alterations. Objective: This study aimed to assess postmortem cerebellar volume in subjects with or without ET, as compared with subjects with multiple system atrophy (MSA), a well-established cerebellar neurodegeneration. Methods: Cases with ET ( n = 29), MSA ( n = 7), and non-demented control cases without any movement disorder ( n = 22) were selected from the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND), a longitudinal clinicopathological study with annual research-dedicated clinical assessments by neuropsychologists, subspecialist movement disorders, and cognitive/behavioral neurologists, with comprehensive neuropathological examinations after death. Group comparisons were controlled for common age-related neurodegenerative and cerebrovascular pathologies. Cerebellar volumes were calculated using digital images of slices taken at the time of autopsy, immediately after brain removal and before fixation. Results: Cerebellar volume was not reduced in ET subjects compared to controls. The two groups did not differ in terms of incidental cerebrovascular and Alzheimer’s disease neuropathology. In contrast, cerebellar volume was significantly reduced in subjects with MSA when compared to ET and control subjects. Conclusion: In a well-characterized cohort, postmortem cerebellar volume measurements suggest that there are no volume alterations in ET when compared to controls, in contrast to significant cerebellar atrophy in subjects with MSA.
Farcimab: a flicker of light in the darkness of neovascular age-related macular degeneration and Diabetes Mellitus – correspondence
Shaikh, Omer Ahmed , Amin, Shifa, Ullah, Irfan , Shaikh, Omer Ahmed , Asghar, Muhammad Sohaib , Ullah, Irfan , Shaikh, Omer Ahmed , Kumari, Kanchan

International Journal of Surgery | March 14, 2023 | Volume: 109 | Issue: 4 | Pages: 1056-1057

10.1097/js9.0000000000000281 | PMID 36917115 Get It

Heart Failure With Preserved Ejection Fraction
Redfield, Margaret M. , Borlaug, Barry A.

JAMA | March 14, 2023 | Volume: 329 | Issue: 10 | Pages: 827

10.1001/jama.2023.2020 | PMID 36917048 Get It

Importance Heart failure with preserved ejection fraction (HFpEF), defined as HF with an EF of 50% or higher at diagnosis, affects approximately 3 million people in the US and up to 32 million people worldwide. Patients with HFpEF are hospitalized approximately 1.4 times per year and have an annual mortality rate of approximately 15%. Observations Risk factors for HFpEF include older age, hypertension, diabetes, dyslipidemia, and obesity. Approximately 65% of patients with HFpEF present with dyspnea and physical examination, chest radiographic, echocardiographic, or invasive hemodynamic evidence of HF with overt congestion (volume overload) at rest. Approximately 35% of patients with HFpEF present with “unexplained” dyspnea on exertion, meaning they do not have clear physical, radiographic, or echocardiographic signs of HF. These patients have elevated atrial pressures with exercise as measured with invasive hemodynamic stress testing or estimated with Doppler echocardiography stress testing. In unselected patients presenting with unexplained dyspnea, the H2FPEF score incorporating clinical (age, hypertension, obesity, atrial fibrillation status) and resting Doppler echocardiographic (estimated pulmonary artery systolic pressure or left atrial pressure) variables can assist with diagnosis (H2FPEF score range, 0-9; score &amp;gt;5 indicates more than 95% probability of HFpEF). Specific causes of the clinical syndrome of HF with normal EF other than HFpEF should be identified and treated, such as valvular, infiltrative, or pericardial disease. First-line pharmacologic therapy consists of sodium-glucose cotransporter type 2 inhibitors, such as dapagliflozin or empagliflozin, which reduced HF hospitalization or cardiovascular death by approximately 20% compared with placebo in randomized clinical trials. Compared with usual care, exercise training and diet-induced weight loss produced clinically meaningful increases in functional capacity and quality of life in randomized clinical trials. Diuretics (typically loop diuretics, such as furosemide or torsemide) should be prescribed to patients with overt congestion to improve symptoms. Education in HF self-care (eg, adherence to medications and dietary restrictions, monitoring of symptoms and vital signs) can help avoid HF decompensation. Conclusions and Relevance Approximately 3 million people in the US have HFpEF. First-line therapy consists of sodium-glucose cotransporter type 2 inhibitors, exercise, HF self-care, loop diuretics as needed to maintain euvolemia, and weight loss for patients with obesity and HFpEF.
Rhabdomyosarcoma with isolated lung metastases: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group
Vasquez, Juan C. , Luo, Leo Y. , Hiniker, Susan M. , Rhee, Daniel S. , Dasgupta, Roshni , Chen, Sonja , Weigel, Brenda J. , Xue, Wei , Venkatramani, Rajkumar , Arndt, Carola A.S., Arndt, Carola A., Dasgupta, Roshni , Luo, Leo Y , Chen, Sonja

Pediatric Blood & Cancer | March 14, 2023 | Volume: 70 | Issue: 6 | Pages: No page available

10.1002/pbc.30293 | PMID 36916768 Get It

Abstract Background To determine outcomes of children with rhabdomyosarcoma (RMS) with isolated lung metastases. Methods Data were analyzed for 428 patients with metastatic RMS treated on COG protocols. Categorical variables were compared using Chi‐square or Fisher's exact tests. Event‐free survival (EFS) and overall survival (OS) were estimated using Kaplan–Meier method and compared using the log‐rank test. Results Compared with patients with other metastatic sites ( n = 373), patients with lung‐only metastases ( n = 55) were more likely to be <10 years of age, have embryonal histology (embryonal rhabdomyosarcoma), have N0 disease, and less likely to have primary extremity tumors. Lung‐only patients had significantly better survival outcomes than patients with all other sites of metastatic disease ( p < .0001) with 5‐year EFS of 48.1 versus 18.8% and 5‐year OS of 64.1 versus 26.9%. Patients with lung‐only metastases, and those with a single extrapulmonary site of metastasis, had better survival compared with patients with two or more sites of metastatic disease ( p < .0001). In patients with ERMS and lung‐only metastases, there was no significant difference in survival between patients ≥10 years and 1–9 years (5‐year EFS: 58.3 vs. 68.2%, 5‐year OS: 66.7 vs. 67.7%). Conclusions With aggressive treatment, patients with ERMS and lung‐only metastatic disease have superior EFS and OS compared with patients with other sites of metastatic disease, even when older than 10 years of age. Consideration should be given to including patients ≥10 years with ERMS and lung‐only metastases in the same group as those <10 years in future risk stratification algorithms.
Integrating Environmental Data with Medical Data in a Records-Linkage System to Explore Groundwater Nitrogen Levels and Child Health Outcomes
Prissel, Christine M. , Klinger, Gregory S., Rocca, Walter A. , Grossardt, Brandon R , Rocca, Walter A , Grossardt, Brandon R. , Sauver, Jennifer L. St.

International Journal of Environmental Research and Public Health | March 14, 2023 | Volume: 20 | Issue: 6 | Pages: 5116

10.3390/ijerph20065116 | PMID 36982025 Get It

Background: The Rochester Epidemiology Project (REP) medical records-linkage system offers a unique opportunity to integrate medical and residency data with existing environmental data, to estimate individual-level exposures. Our primary aim was to provide an archetype of this integration. Our secondary aim was to explore the association between groundwater inorganic nitrogen concentration and adverse child and adolescent health outcomes. Methods: We conducted a nested case-control study in children, aged seven to eighteen, from six counties of southeastern Minnesota. Groundwater inorganic nitrogen concentration data were interpolated, to estimate exposure across our study region. Residency data were then overlaid, to estimate individual-level exposure for our entire study population (n = 29,270). Clinical classification software sets of diagnostic codes were used to determine the presence of 21 clinical conditions. Regression models were adjusted for age, sex, race, and rurality. Results: The analyses support further investigation of associations between nitrogen concentration and chronic obstructive pulmonary disease and bronchiectasis (OR: 2.38, CI: 1.64–3.46) among boys and girls, thyroid disorders (OR: 1.44, CI: 1.05–1.99) and suicide and intentional self-inflicted injury (OR: 1.37, CI: >1.00–1.87) among girls, and attention deficit conduct and disruptive behavior disorders (OR: 1.34, CI: 1.24–1.46) among boys. Conclusions: Investigators with environmental health research questions should leverage the well-enumerated population and residency data in the REP.
Effectiveness of the pre-Omicron COVID-19 vaccines against Omicron in reducing infection, hospitalization, severity, and mortality compared to Delta and other variants: A systematic review
Paul, Pradipta , El-Naas, Ahmed , Hamad, Omar, Salameh, Mohammad , Mhaimeed, Nada , Laswi, Ibrahim , Abdelati, Ali, AlAnni, Jamal, Khanjar, Bushra, Pillai, Krishnadev V., Alroobi, Hasan, Burney, Zain, Mhaimeed, Omar, Bhatti, Mohammad, Sinha, Pratyaksha, Almasri, Muna , Aly, Ahmed, Bshesh, Khalifa , Chamseddine, Reem, Khalil, Omar , D’Souza, Ashton, Shree, Thanu, Mhaimeed, Narjis , Yagan, Lina, Salameh, Mohammad A, Zakaria, Dalia , Salameh, Mohammad A , Alanni, Jamal, Al‐Ali, Dana , Pillai, Krishnadev V., Elshafeey, Abdallah , Aly, Ahmed, Chamseddine, Reem S. , Shree, Thanu, Zakaria, Dalia

Human Vaccines & Immunotherapeutics | March 14, 2023 | Volume: 19 | Issue: 1 | Pages: No page available

10.1080/21645515.2023.2167410 | PMID 36915960 Get It

Therapy-related Myeloid Neoplasms Following PARP Inhibitors—Letter
Batalini, Felipe , Mina, Lida A. , Mina, Alain , Batalini, Felipe , Mina, Lida

Clinical Cancer Research | March 14, 2023 | Volume: 29 | Issue: 6 | Pages: 1157-1157

10.1158/1078-0432.ccr-22-3510 | PMID 36916193 Get It

Immune checkpoint inhibitors in metastatic NSCLC: challenges and future directions (CME article)
Parikh, Kaushal , Sridhar, Arthi , Singh, Pawan Kumar

International Journal of Cancer Care and Delivery | March 14, 2023 | Volume: 3 | Issue: 1 | Pages: No page available

10.53876/001c.72631 Get It

The treatment metastatic non-small cell lung cancer (NSCLC) is largely influenced by the incorporation of immune checkpoint inhibitors (ICI) in the frontline setting. There are several ICI approved for the management of NSCLC based on the PD-L1 expression of the tumors. PD-L1 is a controversial biomarker with various inconsistencies in expression owing to temporal and spatial heterogeneity. Tumor mutational burden is another much studied biomarker associated with its own challenges and questionable concordance with tumor PD-L1 expression. In this article, we aim to discuss the challenges associated with the existing biomarkers, highlighting the need for emerging biomarkers that can help with decision making in the management of this there where several therapeutic options exist. There are emerging “me too” PD-1/PD-L1 drugs which may serve its purpose in many counties where there is limited access to current approved ICIs. What is increasingly apparent is the need to move the needle forward in the treatment of NSCLC and we will discuss the challenges associated with the current therapeutic landscape and the emerging checkpoints and the future directions that are being explored in the management of metastatic NSCLC.